Table 1.
Visit 1 | Visit 2 | P a | |
---|---|---|---|
Age, y | 36 (28–39) | … | |
Ethnicity | |||
Black, non-Hispanic | 17 (46) | … | |
Black, Hispanic | 1 (3) | … | |
Hispanic, all races | 17 (46) | … | |
White, non-Hispanic | 0 (0) | … | |
Refuse to answer | 2 (5) | … | |
Employment status | |||
Disabled | 11 (30) | … | |
Unemployed | 11 (30) | … | |
Employed full time | 5 (13) | … | |
Employed part time | 8 (22) | … | |
Student | 2 (5) | … | |
Experienced homelessness in past 6 mo | 12 (32) | 7 (19) | .06 |
Body mass indexb | 25.8 (22.6–28.5) | 25.3 (21.9–29.2) | .87 |
Time since HIV infection diagnosis, y | 4 (2–12) | … | |
HIV-1 RNA level, log10 copies/mL | 3.41 (1.28–4.56) | 2.56 (1.30–4.05) | .24 |
CD4+ T-cell count | |||
Overall, cells/μL | 427 (319–568) | 532 (302–713) | .01 |
By binc | .10 | ||
0–200 cells/μL | 8 (22) | 4 (11) | |
200–350 cells/μL | 6 (16) | 7 (19) | |
>350 cells/μL | 23 (62) | 26 (70) | |
Currently receiving ART | 30 (81) | 30 (81) | >.99 |
ART regimen | .99 | ||
NNRTI | 10 (27) | 9 (24) | |
PI | 8 (22) | 9 (24) | |
INSTI | 10 (27) | 10 (27) | |
NNRTI + INSTI | 1 (3) | 1 (3) | |
PI + INSTI | 1 (3) | 1 (3) | |
STI prevalence | |||
Syphilisd | 0 | 2 (5) | .16 |
N. gonorrhoeae infection | |||
Rectal | 3 (8) | 4 (11) | .66 |
Urinary | 0 | 0 | |
Pharyngeal | 2 (5) | 2 (5) | >.99 |
C. trachomatis infection | |||
Rectal | 5 (14) | 2 (5) | .08 |
Urinary | 2 (5) | 0 | .16 |
Pharyngeal | 1 (3) | 1 (3) | >.99 |
Frequency of alcohol use in past 6 mo | <.001 | ||
Never | 5 (13) | 9 (24) | |
Monthly | 7 (19) | 10 (27) | |
2–4 times/mo | 13 (35) | 9 (24) | |
2–3 times/wk | 4 (11) | 2 (5) | |
≥4 times/wk | 7 (19) | 5 (14) | |
Refuse to answer | 1 (3) | 2 (5) | |
Frequency of smoking in past 6 mo | <.001 | ||
Never | 5 (13) | 9 (24) | |
Monthly | 7 (19) | 10 (27) | |
2–4 times/mo | 13 (35) | 9 (24) | |
2–3 times/wk | 4 (11) | 2 (5) | |
≥4 times/wk | 7 (19) | 5 (14) | |
Refuse to answer | 1 (3) | 2 (5) |
Data are median value (interquartile range) or no. (%) of participants.
Abbreviations: ART, antiretroviral therapy; C. trachomatis, Chlamydia trachomatis; HIV-1, human immunodeficiency virus type 1; INSTI, integrase strand transfer inhibitor; N. gonorrhoeae, Neisseria gonorrhoeae; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STI, sexually transmitted infection.
aBinary variables were compared using by the McNemar test; continuous variables, using the Wilcoxon signed rank test; ordinal variables, using mixed ordinal logistic regression; and N×N (N > 2) nominal variables, using mixed multinomial logistic regression models.
bCalculated as the weight in kilograms divided by the height in meters squared.
cVisit 1 includes missing data (CD4+ T-cell counts for 6 participants) that were predicted using multiple imputation methods.
dDetected by a rapid plasma reagin screen.